A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

Annals of Oncology

Volumn 15, Issue 9, 2004, Pages 1358-1365

  Tabernero, J ^a   Climent, M A ^b   Lluch, A ^c   Albanell, J ^a   Vermorken, J B ^d   Barnadas, A ^e   Anton A ^f   Laurent, C ^g   Mayordomo, J I ^f   Estaun, N ^a   Losa, I ^h   Guillem, V ^b   Garcia Conde, J ^c   Tisaire, J L ^h   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f Medical Oncology Service   (Spain)

^g Operations Department   (Belgium)

^h Aventis Pharma   (Spain)

Author keywords

Docetaxel; Metastatic breast cancer; Randomised trial

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DOCETAXEL; MITOMYCIN C; NITROSOUREA; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; INFECTION; INTERMETHOD COMPARISON; LACRIMAL GLAND DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; ONYCHOLYSIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4644357450     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh349     Document Type: Article

References (31)

1. Crown J. Docetaxel: overview of an active drug for breast cancer. Oncologist 2001; 6 (Suppl 3): 1-4.
2. Nabholtz JM, Riva A. Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 2001; 6 (Suppl 3): 5-12.
3. Esteva FJ. The current status of docetaxel for metastatic breast cancer. Oncology (Huntingt) 2002; 16: 17-26.
4. Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 2001; 6 (Suppl 3): 26-29.
5. Ravdin PM. Treatment of patients resistant to anthracycline therapy. Anticancer Drugs 1996; 7 (Suppl 2): 13-16.
6. Nabholtz JM, Tonkin K, Smylie M et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000; 1: 187-206.
7. Klaassen U, Wilke H, Strumberg D et al. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996; 32A: 547-549.
8. Briasoulis E, Tzamakou E, Nicolaides C et al. Long-term weekly administration of paclitaxel in chemotherapy-naive patients, phase I study. Proc ASCO 1997; 16: 231a (Abstr 811).
9. Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-3361.
10. Lück HJ, Donne S, Glaubitz M et al. Phase I study of weekly docetaxel (Taxotere®) in heavily pretreated breast cancer patients. Eur J Cancer 1997; 33: S158 (Abstr 703).
11. Hainsworth JD, Burris HA, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-2168.
12. Briasoulis E, Karavasilis V, Anastasopoulos D et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10: 701-706.
13. Droge C, Freund W, Hausamen TU et al. Activity of weekly Taxotere® (TXT) in patients with metastatic breast cancer. Proc ASCO 1998; 17: 113 (Abstr 435).
14. Climent M, Dorta J, Fernandez-Martos C et al. Weekly docetaxel in patients with advanced malignancies: toxicity profile and activity results. Proc ASCO 1999; 18: 119 (Abstr 453).
15. Loffler TM. Is there a place for 'dose-dense' weekly schedules of the taxoids? Semin Oncol 1998; 25: 32-34.
16. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18: 1212-1219.
17. Gonzalez-Ageitos A, Ramos M. Weekly docetaxel (D) for metastatic breast cancer (MBC) progressing after anthracyclines treatment. Proc ASCO 2000; 19: 115 (Abstr 445).
18. Eibach H, Hohlweg-Majert P, Jackisch C et al. Phase-II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC). Proc ASCO 2000; 19: 108 (Abstr 417).
19. Stemmler HJ, Gutschow K, Sommer H et al. Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Ann Oncol 2001; 12: 1393-1398.
20. Aihara T, Aritake N, Gotou K et al. Weekly docetaxel for patients with recurrent breast cancer: clinical results and pharmacokinetic/pharmacodynamic assessment. Proc ASCO 2000; 19: 113 (Abstr 436).
21. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001; 6 (Suppl 3): 30-35.
22. National Cancer Institute. Guidelines for the Reporting of Adverse Drugs Reactions. Bethesda, MD: Division of Cancer Treatment 1988.
23. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
24. Kaplan EL. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 47: 457-481.
25. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-1424.
26. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
27. Mey U, Gorschlüter M, Ziske C et al. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 2003; 14: 233-238.
28. Hainsworth JD, Burris HA III, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19: 3500-3505.
29. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13: 286-292.
30. Adachi I, Watanabe T, Takashima S et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210-216.
31. Camps C, Massuti A, Jimenez I et al. Second-line docetaxel administered every 3-weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial. Proc ASCO 2003; 22: 625 (Abstr 2514).